Home  |  Contact

Cellosaurus MCF-7 (CVCL_0031)

[Text version]

Cell line name MCF-7
Synonyms MCF 7; MCF.7; MCF7; Michigan Cancer Foundation-7; ssMCF-7; ssMCF7; MCF7/WT; IBMF-7; MCF7-CTRL
Accession CVCL_0031
Resource Identification Initiative To cite this cell line use: MCF-7 (RRID:CVCL_0031)
Comments Group: Space-flown cell line (cellonaut).
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 2.
Part of: JFCR39 cancer cell line panel.
Part of: JFCR45 cancer cell line panel.
Part of: GrayJW Breast Cancer Cell Line Panel.
Part of: ICBP43 breast cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
Registration: Chiron Master Culture Collection; CMCC 10377 (CMCC #10377).
Doubling time: 1.8 days (PubMed=9671407); 80 hours (PubMed=25984343); 31.2 hours (PubMed=22628656); 25.4 hours (NCI-DTP); ~50 hours, with a range of 30-72 hours (DSMZ); ~38 hours (PBCF); 56.47 hours (https://www.synapse.org/#!Synapse:syn2347014).
Microsatellite instability: Stable (MSS) (PubMed=12661003; PubMed=23671654; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep phosphoproteome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: Glycoproteome analysis by proteomics.
Omics: H3K27ac ChIP-seq epigenome analysis.
Omics: H3K27me3 ChIP-seq epigenome analysis.
Omics: H3K36me3 ChIP-seq epigenome analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: H3K9me3 ChIP-seq epigenome analysis.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: miRNA expression profiling.
Omics: Myristoylated proteins analysis by proteomics.
Omics: N-glycan profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Omics: Virome analysis using proteomics.
Anecdotal: This is the first hormone-responsive breast cancer cell line to have been established.
Anecdotal: Helen Mallon (sister Catherine Frances), the patient from which this cell line is derived was a nun (Sister Catherine Frances) at the Immaculate Heart of Mary Convent in Monroe, Michigan.
Anecdotal: Have been flown in space on Foton-12 to study cytoskeleton architecture in microgravity (PubMed=11292682; PubMed=15002416).
Misspelling: MFC-7; Occasionally.
Sequence variations Homozygous for CDKN2A deletion (PubMed=19593635).
Heterozygous for PIK3CA p.Glu545Lys (c.1633G>A) (PubMed=17088437; PubMed=19593635; PubMed=28889351).
Has no TP53 mutation (PubMed=15900046).
HLA typing Source: PubMed=15748285
Class I
Class II

Source: PubMed=25960936
Class I
Class II
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0
East Asian, North4.2
East Asian, South0
South Asian0
European, North56.91
European, South38.15
Disease Invasive ductal carcinoma, not otherwise specified (NCIt: C4194)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_1D32 (AREc32)CVCL_X007 (hTERT-EEC-B37)CVCL_2094 (KPL-1)
CVCL_0404 (M7TS90)CVCL_4Y65 (MCF-7 clone 33)CVCL_HA11 (MCF-7 eGFP-CEBPG)
CVCL_UU88 (MCF-7 M21)CVCL_UU89 (MCF-7 M27)CVCL_LB51 (MCF-7 MX20)
CVCL_IU97 (MCF-7 RR2)CVCL_RA89 (MCF-7 shPARG)CVCL_S030 (MCF-7 SimpleCell O-GalNAc)
CVCL_IU98 (MCF-7 TKi-R)CVCL_4Y54 (MCF-7-2a)CVCL_DC70 (MCF-7.5C)
CVCL_R954 (MCF-7-BAG)CVCL_4V96 (MCF-7-EpiR)CVCL_5I64 (MCF-7-FLV1000)
CVCL_J259 (MCF-7-Luc)CVCL_5J35 (MCF-7-luc-F5)CVCL_5J04 (MCF-7-Red-Fluc)
CVCL_4V97 (MCF-7-TaxR)CVCL_0412 (MCF-7/2a)CVCL_4V53 (MCF-7/4-HC)
CVCL_4V44 (MCF-7/5-23)CVCL_W972 (MCF-7/6)CVCL_4Y46 (MCF-7/AdrVp)
CVCL_W971 (MCF-7/AZ)CVCL_GX99 (MCF-7/C4-12)CVCL_4D03 (MCF-7/CG-4)
CVCL_4D04 (MCF-7/CG-5)CVCL_HA20 (MCF-7/E2F1)CVCL_M439 (MCF-7/E6)
CVCL_5J37 (MCF-7/GFP)CVCL_0U80 (MCF-7/HER2-18)CVCL_5J36 (MCF-7/Luc)
CVCL_9579 (MCF-7/LY2)CVCL_Z704 (MCF-7/MDD2)CVCL_Z705 (MCF-7/MN1)
CVCL_4V43 (MCF-7/RTx6)CVCL_K235 (MCF-7/RU58R-1)CVCL_1D47 (MCF-7/S0.5)
CVCL_M355 (MCF-7/Taxol)CVCL_4V42 (MCF-7/TPT300)CVCL_DR99 (MCF-7/Twist)
CVCL_2Z97 (MCF-7/VD(R))CVCL_5I65 (MCF-7/VP)CVCL_4Y53 (MCF-7:2A)
CVCL_9580 (MCF-7aro)CVCL_6860 (MCF-7B)CVCL_2Z98 (MCF-7D3Res)
CVCL_0088 (MCF-7L)CVCL_6672 (MCF-7M)CVCL_6673 (MCF-7N)
CVCL_M373 (MCF3B)CVCL_DF45 (MCF7 NucLight Green)CVCL_DF46 (MCF7 NucLight Red)
CVCL_V357 (MCF7 Tet-Off)CVCL_KU37 (MCF7 Tet-Off advanced)CVCL_V332 (MCF7 Tet-On)
CVCL_KU45 (MCF7 Tet-On Advanced)CVCL_V358 (MCF7 tTS)CVCL_3397 (MCF7-382)
CVCL_3398 (MCF7-422)CVCL_3399 (MCF7-432)CVCL_3400 (MCF7-488X1)
CVCL_3401 (MCF7-490X1)CVCL_3402 (MCF7-492X1)CVCL_4V66 (MCF7-AFA[r])
CVCL_VH35 (MCF7-B7-TS)CVCL_XD68 (MCF7-Cas9-542)CVCL_XD69 (MCF7-Cas9-543)
CVCL_XD70 (MCF7-Cas9-544)CVCL_VR08 (MCF7-h14)CVCL_EG55 (MCF7-TamR)
CVCL_0413 (MCF7/BUS)CVCL_EQ28 (MCF7/c)CVCL_M437 (MCF7/D40)
CVCL_0415 (MCF7mp53)CVCL_R955 (MCS-2)CVCL_WI91 (MELN)
Originate from same individual CVCL_N481 ! Hs 631.T
Sex of cell Female
Age at sampling 69Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=17254797; PubMed=19372543; PubMed=25321415; PubMed=25877200; PubMed=27456714; PubMed=28889351; RCB; TKG

D5S81811,12 (AddexBio; ATCC; CCRID; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=17254797; PubMed=19372543; PubMed=25321415; PubMed=25877200; PubMed=27456714; PubMed=28889351; RCB; TKG)
12 (CLS)
FGA23,24,25 (CCRID)
23,25 (CLS; PubMed=17254797; PubMed=19372543; PubMed=25877200)
Penta D12
Penta E7,12

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/MCF-7

PubMed=4357757; DOI=10.1093/jnci/51.5.1409
Soule H.D., Vazguez J., Long A., Albert S., Brennan M.
A human cell line from a pleural effusion derived from a breast carcinoma.
J. Natl. Cancer Inst. 51:1409-1416(1973)

Lippman M.E., Bolan G., Huff K.
The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4595-4601(1976)

Lippman M.E., Bolan G., Huff K.
The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4602-4609(1976)

Lippman M.E., Bolan G., Huff K.
The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4610-4618(1976)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

Nawata H., Bronzert D., Lippman M.E.
Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells.
J. Biol. Chem. 256:5016-5021(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3702420; DOI=10.1016/0022-4731(86)90083-X
Devleeschouwer N., Olea-Serrano N., Leclercq G., Legros N., Heuson J.C.
Induction of progesterone receptor in an estrogen, progesterone receptor-negative breast cancer cell line.
J. Steroid Biochem. 24:365-368(1986)

PubMed=1911442; DOI=10.1016/0960-0760(91)90248-4
Wild M.J., Rudland P.S., Back D.J.
Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal (Huma 7) and malignant (MCF-7 and ZR-75-1) human breast cells in culture.
J. Steroid Biochem. Mol. Biol. 39:535-543(1991)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

Leibovitz A.
Cell lines from human breast.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994)

Rostagno P., Moll J.-L., Birtwisle-Peyrottes I., Ettore F., Lagrange J.-L., Gioanni J., Caldani C.
Effects of tamoxifen on potential doubling time of human breast cancer cell line determined by image cytometry of double fluorescent BrdU and DNA labeling.
Anticancer Res. 14:2025-2032(1994)

PubMed=7498097; DOI=10.1289/ehp.95103844
Villalobos M., Olea N., Brotons J.A., Olea-Serrano M.F., Ruiz de Almodovar J.M., Pedraza V.
The E-screen assay: a comparison of different MCF7 cell stocks.
Environ. Health Perspect. 103:844-850(1995)

PubMed=8626706; DOI=10.1074/jbc.271.19.11477
Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F.
Insulin-like growth factor expression in human cancer cell lines.
J. Biol. Chem. 271:11477-11483(1996)

PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Int. J. Cancer 67:816-820(1996)

Levenson A.S., Jordan V.C.
MCF-7: the first hormone-responsive breast cancer cell line.
Cancer Res. 57:3071-3078(1997)

PubMed=9671407; DOI=10.1038/sj.onc.1201814
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Oncogene 16:2865-2878(1998)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B
Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F., Isola J., Larsson C.
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Genes Chromosomes Cancer 28:308-317(2000)

PubMed=11044355; DOI=10.1054/bjoc.2000.1458
Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C., Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Molecular cytogenetic analysis of breast cancer cell lines.
Br. J. Cancer 83:1309-1317(2000)

PubMed=11078910; DOI=10.1016/S0304-3835(00)00579-6
Lilling G., Hacohen H., Nordenberg J., Livnat T., Rotter V., Sidi Y.
Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio?
Cancer Lett. 161:27-34(2000)

PubMed=11292682; DOI=10.1096/fj.00-0527fje
Vassy J., Portet S., Beil M., Millot G., Fauvel-Lafeve F., Karniguian A., Gasset G., Irinopoulou T., Calvo F., Rigaut J.P., Schoevaert D.
The effect of weightlessness on cytoskeleton architecture and proliferation of human breast cancer cell line MCF-7.
FASEB J. 15:1104-1106(2001)

PubMed=11789735; DOI=10.1309/4NCM-QJ9W-QM0J-6QJE
Rhodes A., Jasani B., Couturier J., McKinley M.J., Morgan J.M., Dodson A.R., Navabi H., Miller K.D., Balaton A.J.
A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
Am. J. Clin. Pathol. 117:81-89(2002)

PubMed=12353263; DOI=10.1002/gcc.10107
Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Genes Chromosomes Cancer 35:204-218(2002)

PubMed=12661003; DOI=10.1002/gcc.10196
Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.-F., Schlag P.M., Scherneck S.
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Genes Chromosomes Cancer 37:29-35(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=15002416; DOI=10.1016/S0273-1177(03)90400-5
Vassy J., Portet S., Beil M., Millot G., Fauvel-Lafeve F., Gasset G., Schoevaert D.
Weightlessness acts on human breast cancer cell line MCF-7.
Adv. Space Res. 32:1595-1603(2003)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11-11(2005)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=16142302; DOI=10.3892/ijo.27.4.881
de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.
Molecular characterization of breast cancer cell lines by a low-density microarray.
Int. J. Oncol. 27:881-892(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Tehrani M.J., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)

PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004
Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J.
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
Mol. Oncol. 1:84-96(2007)

PubMed=18386134; DOI=10.1007/s10585-008-9169-z
Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.
Clin. Exp. Metastasis 25:549-557(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

PubMed=19727395; DOI=10.1371/journal.pone.0006888
Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R., Finn S., Loda M., Mahmood U., Ramaswamy S.
Systems-level modeling of cancer-fibroblast interaction.
PLoS ONE 4:E6888-E6888(2009)

Morrison B.J.
Breast cancer stem cells: tumourspheres and implications for therapy.
Thesis PhD (2010), Griffith University, Australia

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=20070913; DOI=10.1186/1471-2407-10-15
Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
BMC Cancer 10:15-15(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

Fang R., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=21247443; DOI=10.1186/gb-2011-12-1-r6
Edgren H., Murumagi A., Kangaspeska S., Nicorici D., Hongisto V., Kleivi K., Rye I.H., Nyberg S., Wolf M., Borresen-Dale A.-L., Kallioniemi O.
Identification of fusion genes in breast cancer by paired-end RNA-sequencing.
Genome Biol. 12:R6.1-R6.13(2011)

Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.
Reassessment of estrogen receptor expression in human breast cancer cell lines.
Anticancer Res. 31:521-527(2011)

PubMed=22278370; DOI=10.1074/mcp.M111.014050
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22414580; DOI=10.1158/0008-5472.CAN-11-3711
Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M.
Proteomic portrait of human breast cancer progression identifies novel prognostic markers.
Cancer Res. 72:2428-2439(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez F., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23285151; DOI=10.1371/journal.pone.0052692
Morrison B.J., Hastie M.L., Grewal Y.S., Bruce Z.C., Schmidt C., Reynolds B.A., Gorman J.J., Lopez J.A.
Proteomic comparison of MCF-7 tumoursphere and monolayer cultures.
PLoS ONE 7:E52692-E52692(2012)

Crane A., Brennan M., Naebers R.
Catherine Frances Mallon's 'immortal cells'.
IHM Arch. Notes 4:2.1-2.1(2013)

PubMed=23234512; DOI=10.1021/pr300898u
Segura V., Medina-Aunon J.A., Guruceaga E., Gharbi S.I., Gonzalez-Tejedo C., Sanchez del Pino M.M., Canals F., Fuentes M., Casal J.I., Martinez-Bartolome S., Elortza F., Mato J.M., Arizmendi J.M., Abian J., Oliveira E., Gil C., Vivanco F., Blanco F., Albar J.P., Corrales F.J.
Spanish human proteome project: dissection of chromosome 16.
J. Proteome Res. 12:112-122(2013)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33-R33(2013)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=23770244; DOI=10.1016/j.celrep.2013.05.024
Wierer M., Verde G., Pisano P., Molina H., Font-Mateu J., Di Croce L., Beato M.
PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.
Cell Rep. 3:2021-2032(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23868472; DOI=10.1038/ncomms3175
Johansson H.J., Sanchez B.C., Mundt F., Forshed J., Kovacs A., Panizza E., Hultin-Rosenberg L., Lundgren B., Martens U., Mathe G., Yakhini Z., Helou K., Krawiec K., Kanter L., Hjerpe A., Stal O., Linderholm B.K., Lehtio J.
Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer.
Nat. Commun. 4:2175-2175(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24009699; DOI=10.1371/journal.pone.0072704
Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P., Shi S.-L., Chen C.-Y., Li Y.
Cell surface-specific N-glycan profiling in breast cancer.
PLoS ONE 8:E72704-E72704(2013)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3
Prat A., Karginova O., Parker J.S., Fan C., He X., Bixby L., Harrell J.C., Roman E., Adamo B., Troester M., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J., Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=24618588; DOI=10.1371/journal.pone.0091433
Chernobrovkin A.L., Zubarev R.A.
Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.
PLoS ONE 9:E91433-E91433(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25321415; DOI=10.1210/me.2014-1229
Li Y., Arao Y., Hall J.M., Burkett S., Liu L., Gerrish K., Cavailles V., Korach K.S.
Research resource: STR DNA profile and gene expression comparisons of human BG-1 cells and a BG-1/MCF-7 clonal variant.
Mol. Endocrinol. 28:2072-2081(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25807930; DOI=10.1002/anie.201500342
Broncel M., Serwa R.A., Ciepla P., Krause E., Dallman M.J., Magee A.I., Tate E.W.
Multifunctional reagents for quantitative proteome-wide analysis of protein modification in human cells and dynamic profiling of protein lipidation during vertebrate development.
Angew. Chem. Int. Ed. 54:5948-5951(2015)

PubMed=25828948; DOI=10.1093/jnci/djv073
Lee A.V., Oesterreich S., Davidson N.E.
MCF-7 cells -- changing the course of breast cancer research and care for 45 years.
J. Natl. Cancer Inst. 107:djv073.1-djv073.4(2015)

Comsa S., Cimpean A.M., Raica M.
The story of MCF-7 breast cancer cell line: 40 years of experience in research.
Anticancer Res. 35:3147-3154(2015)

PubMed=26055192; DOI=10.1021/acs.jproteome.5b00375
Cifani P., Kirik U., Waldemarson S., James P.
Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors.
J. Proteome Res. 14:2819-2827(2015)

PubMed=26330541; DOI=10.1074/mcp.M115.050484
Wu X., Zahari M.S., Renuse S., Nirujogi R.S., Kim M.-S., Manda S.S., Stearns V., Gabrielson E., Sukumar S., Pandey A.
Phosphoproteomic analysis identifies focal adhesion kinase 2 (FAK2) as a potential therapeutic target for tamoxifen resistance in breast cancer.
Mol. Cell. Proteomics 14:2887-2900(2015)

PubMed=27331101; DOI=10.1016/j.dib.2016.05.040
Aumsuwan P., Khan S.I., Khan I.A., Walker L.A., Dasmahapatra A.K.
Gene expression profiling and pathway analysis data in MCF-7 and MDA-MB-231 human breast cancer cell lines treated with dioscin.
Data Brief 8:272-279(2016)

PubMed=27362937; DOI=10.1371/journal.pone.0157290
Carrier M., Joint M., Lutzing R., Page A., Rochette-Egly C.
Phosphoproteome and transcriptome of RA-responsive and RA-resistant breast cancer cell lines.
PLoS ONE 11:E0157290-E0157290(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27456714; DOI=10.1038/srep28994
Kleensang A., Vantangoli M.M., Odwin-DaCosta S., Andersen M.E., Boekelheide K., Bouhifd M., Fornace A.J. Jr., Li H.-H., Livi C.B., Madnick S., Maertens A., Rosenberg M., Yager J.D., Zhaog L., Hartung T.
Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function.
Sci. Rep. 6:28994-28994(2016)

PubMed=27761513; DOI=10.1016/j.dib.2016.09.025
Sarvaiya H.A., Lazar I.M.
Insulin stimulated MCF7 breast cancer cells: proteome dataset.
Data Brief 9:579-584(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
J. Proteome Res. 16:1391-1400(2017)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cell line collections AddexBio; C0006008/402
ATCC; CRL-12584 - Discontinued
BCRC; 60436
BCRJ; 0162
CLS; 300273/p2720_MCF-7
ECACC; 86012803
IBRC; C10082
IBRC; C10682
ICLC; HTL95021
JCRB; NIHS0200 - Discontinued
KCB; KCB 200529YJ
KCB; KCB 200831YJ
KCLB; 30022
NCBI_Iran; C135
RCB; RCB1904
TKG; TKG 0479
Cell line databases/resources CLDB; cl3366
CLDB; cl3367
CLDB; cl3368
CLDB; cl3369
CLDB; cl3370
CLDB; cl3371
CLDB; cl3372
CLDB; cl3373
CLDB; cl3375
CCRID; 3111C0001CCC000013
CCRID; 3111C0001CCC000328
CCRID; 3131C0001000700074
CCRID; 3142C0001000000054
Cell_Model_Passport; SIDM00148
Cosmic-CLP; 905946
DepMap; ACH-000019
GDSC; 905946
LINCS_HMS; 50029
Lonza; 113
TOKU-E; 2383
TOKU-E; 3748
Ontologies BTO; BTO:0000093
CLO; CLO_0007601
CLO; CLO_0007605
CLO; CLO_0007606
CLO; CLO_0050868
EFO; EFO_0001203
MCCL; MCC:0000307
MeSH; D061986
Biological sample resources BioSample; SAMN01821575
BioSample; SAMN01821646
BioSample; SAMN01821698
BioSample; SAMN03473276
BioSample; SAMN05292458
BioSample; SAMN10988179
Chemistry resources ChEMBL-Cells; CHEMBL3308403
ChEMBL-Targets; CHEMBL387
PharmacoDB; MCF7_895_2019
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-TABM-157
ArrayExpress; E-TABM-244
GEO; GSM1723
GEO; GSM2111
GEO; GSM2137
GEO; GSM2153
GEO; GSM50183
GEO; GSM50247
GEO; GSM69199
GEO; GSM73693
GEO; GSM115111
GEO; GSM155207
GEO; GSM156025
GEO; GSM185091
GEO; GSM185092
GEO; GSM211175
GEO; GSM274640
GEO; GSM276773
GEO; GSM276774
GEO; GSM276775
GEO; GSM276776
GEO; GSM276777
GEO; GSM276778
GEO; GSM276779
GEO; GSM320172
GEO; GSM344347
GEO; GSM344397
GEO; GSM350552
GEO; GSM378140
GEO; GSM388212
GEO; GSM421869
GEO; GSM459726
GEO; GSM472936
GEO; GSM481303
GEO; GSM510510
GEO; GSM533396
GEO; GSM533413
GEO; GSM590108
GEO; GSM679692
GEO; GSM679693
GEO; GSM679694
GEO; GSM736581
GEO; GSM736588
GEO; GSM739996
GEO; GSM739997
GEO; GSM739998
GEO; GSM750771
GEO; GSM750777
GEO; GSM750778
GEO; GSM750801
GEO; GSM783949
GEO; GSM799320
GEO; GSM799383
GEO; GSM816438
GEO; GSM816627
GEO; GSM816670
GEO; GSM822295
GEO; GSM822305
GEO; GSM825711
GEO; GSM827593
GEO; GSM847394
GEO; GSM847490
GEO; GSM844586
GEO; GSM844587
GEO; GSM887291
GEO; GSM888366
GEO; GSM923442
GEO; GSM935445
GEO; GSM935477
GEO; GSM935563
GEO; GSM945269
GEO; GSM945274
GEO; GSM945854
GEO; GSM945857
GEO; GSM967819
GEO; GSM967823
GEO; GSM970217
GEO; GSM970218
GEO; GSM987741
GEO; GSM987742
GEO; GSM987743
GEO; GSM1008565
GEO; GSM1008581
GEO; GSM1008603
GEO; GSM1008904
GEO; GSM1010734
GEO; GSM1010764
GEO; GSM1010768
GEO; GSM1010769
GEO; GSM1010783
GEO; GSM1010791
GEO; GSM1010800
GEO; GSM1010811
GEO; GSM1010825
GEO; GSM1010837
GEO; GSM1010838
GEO; GSM1010839
GEO; GSM1010844
GEO; GSM1010860
GEO; GSM1010861
GEO; GSM1010862
GEO; GSM1010863
GEO; GSM1010864
GEO; GSM1010889
GEO; GSM1010891
GEO; GSM1010892
GEO; GSM1022658
GEO; GSM1022663
GEO; GSM1029440
GEO; GSM1029441
GEO; GSM1029442
GEO; GSM1029443
GEO; GSM1029444
GEO; GSM1029445
GEO; GSM1029446
GEO; GSM1029447
GEO; GSM1029448
GEO; GSM1029449
GEO; GSM1040306
GEO; GSM1040376
GEO; GSM1053687
GEO; GSM1068138
GEO; GSM1068139
GEO; GSM1153389
GEO; GSM1172885
GEO; GSM1181258
GEO; GSM1181263
GEO; GSM1214589
GEO; GSM1238132
GEO; GSM1374643
GEO; GSM1374644
GEO; GSM1374645
GEO; GSM1401653
GEO; GSM1670076
GEO; GSM1833626
GEO; GSM2046560
GEO; GSM2046561
GEO; GSM2046562
GEO; GSM2046563
GEO; GSM2046564
GEO; GSM2046565
GEO; GSM2046566
GEO; GSM2046567
GEO; GSM2046568
GEO; GSM2046569
GEO; GSM2046570
GEO; GSM2046571
GEO; GSM2046572
GEO; GSM2046573
GEO; GSM2046574
GEO; GSM2046575
GEO; GSM2046576
GEO; GSM2046577
GEO; GSM2046578
GEO; GSM2046579
GEO; GSM2046580
GEO; GSM2046581
GEO; GSM2046582
GEO; GSM2046583
GEO; GSM2046584
GEO; GSM2046585
GEO; GSM2046586
GEO; GSM2046587
GEO; GSM2046588
GEO; GSM2046589
GEO; GSM2046590
GEO; GSM2046591
GEO; GSM2046592
GEO; GSM2046593
GEO; GSM2046594
GEO; GSM2046595
GEO; GSM2046596
GEO; GSM2046597
GEO; GSM2046598
GEO; GSM2046599
GEO; GSM2046600
GEO; GSM2046601
GEO; GSM2046602
GEO; GSM2046603
GEO; GSM2046604
GEO; GSM2046605
GEO; GSM2046606
GEO; GSM2046607
GEO; GSM2095708
GEO; GSM2095709
GEO; GSM2124642
GEO; GSM2136630
GEO; GSM2136631
GEO; GSM2136632
GEO; GSM2136633
GEO; GSM2136634
GEO; GSM2136635
GEO; GSM2176269
GEO; GSM2176270
Metabolomic databases MetaboLights; MTBLS177
MetaboLights; MTBLS182
MetaboLights; MTBLS241
MetaboLights; MTBLS337
MetaboLights; MTBLS430
Other Wikidata; Q1881253
Polymorphism and mutation databases Cosmic; 687490
Cosmic; 755293
Cosmic; 809239
Cosmic; 871143
Cosmic; 875876
Cosmic; 877449
Cosmic; 894096
Cosmic; 897419
Cosmic; 904373
Cosmic; 905946
Cosmic; 912001
Cosmic; 921976
Cosmic; 923059
Cosmic; 934534
Cosmic; 944293
Cosmic; 947352
Cosmic; 949189
Cosmic; 970089
Cosmic; 979723
Cosmic; 991328
Cosmic; 997916
Cosmic; 1000123
Cosmic; 1010932
Cosmic; 1017161
Cosmic; 1018463
Cosmic; 1019310
Cosmic; 1046936
Cosmic; 1047712
Cosmic; 1066224
Cosmic; 1071901
Cosmic; 1092612
Cosmic; 1102382
Cosmic; 1136341
Cosmic; 1152527
Cosmic; 1175832
Cosmic; 1176603
Cosmic; 1176648
Cosmic; 1183770
Cosmic; 1287893
Cosmic; 1289391
Cosmic; 1305382
Cosmic; 1308991
Cosmic; 1312369
Cosmic; 1326278
Cosmic; 1434950
Cosmic; 1436031
Cosmic; 1477426
Cosmic; 1481420
Cosmic; 1523770
Cosmic; 1524349
Cosmic; 1571788
Cosmic; 1603215
Cosmic; 1609459
Cosmic; 1945860
Cosmic; 1995500
Cosmic; 1998454
Cosmic; 2162161
Cosmic; 2165024
Cosmic; 2301233
Cosmic; 2301526
Cosmic; 2307194
Cosmic; 2318370
Cosmic; 2361358
Cosmic; 2525755
Cosmic; 2553502
Cosmic; 2560248
Cosmic; 2668278
IARC_TP53; 21079
LiGeA; CCLE_648
Proteomic databases PRIDE; PXD000275
PRIDE; PXD000281
PRIDE; PXD000309
PRIDE; PXD000442
PRIDE; PXD000623
PRIDE; PXD000691
PRIDE; PXD001274
PRIDE; PXD001352
PRIDE; PXD001812
PRIDE; PXD001863
PRIDE; PXD002104
PRIDE; PXD002192
PRIDE; PXD002395
PRIDE; PXD002421
PRIDE; PXD002998
PRIDE; PXD003704
PRIDE; PXD004051
PRIDE; PXD004085
PRIDE; PXD004357
PRIDE; PXD005032
PRIDE; PXD005390
PRIDE; PXD005940
PRIDE; PXD005942
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number32